Chronic Lymphocytic Leukemia Coverage from Every Angle
Advertisement
Advertisement

John C. Byrd, MD, on Long-Term Follow-up of Acalabrutinib Treatment in CLL/SLL

Posted: Wednesday, July 8, 2020

John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the significance of the mature data reported in a phase II study supporting favorable results with acalabrutinib in phase III trials, the challenge of long-term side effects, and how to manage them.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.